A major challenge in combating infectious disease is the development of new or more potent antibiotic treatments. Unfortunately, discovering new antibiotics is technically challenging, costly and timeconsuming (Payne et al., 2007) . However, a recent discovery by Evgeny Nudler and colleagues at New York University (NYU) may help make the drugs, we currently have, more potent (Gusarov et al., 2009) . Moreover, the work has shed new light on the many and sundry biological roles of a most mercurial molecule, nitric oxide (NO). First discovered as an intermediate in bacterial anaerobic respiration (i.e. denitrification), and later found to be a key signaling molecule and cytotoxic agent of eukaryotic cells, the importance of NO in biology continues to expand (Sudhamsu and Crane, 2009) . In mammals, NO is produced from the amino acid arginine by the nitric oxide synthases (NOSs) (Alderton et al., 2001) . Bacteria also contain homologs of NOS, but up until recently, their function has not been well understood (Sudhamsu and Crane, 2009 ). Nudler's group has shown that in bacilli and staphylococci, NOS plays a role in protection against oxidative stress (Gusarov and Nudler, 2005; Shatalin et al., 2008) . This could be important for drug therapy because bactericidal antibiotics (divided in three different classes, the lactams, aminoglycosides and quinolones) cause cell death through the formation of reactive oxygen species (ROS) induced by metabolic feedback (Kohanski et al., 2007) . To test if NOS can mitigate the toxicity of ROS produced by antibiotics, Nudler and colleagues treated wt and nos mutant strains of the soil bacterium Bacillus subtilis with many different compounds and monitored the cell growth on a large scale using a Phenotype MicroArraybased screen (Gusarov et al., 2009) . They found that some bactericidal antibiotics preferentially inhibited the growth of the nos mutant. Antibiotics that were particularly potent in the absence of NOS were subjected to further study.
Acriflavine (ACR, Figure 1A ) belongs to the quinolone class of antibiotics, which have long been known to interfere with bacterial DNA replication (Payne et al., 2007) . Toxicity of the compound derives in part from its two aromatic amino groups. The nitronum cation NO + , produced by oxidation of NO, reacts directly with ACR to eventually produce the less toxic dihydroxyacridine derivative and N 2 gas. Indeed, premixing ACR and NO prior to inoculation reduced killing of B. subtilis or Staphylococcus aureus. A related compound, acridine orange (AO), was unaffected by NO treatment because it has methylated arylamino groups that do not react with NO. As a result, AO showed much less discrimination between the Dnos and wt strains than ACR. Overexpression of NOS in Escherichia coli, a bacterium that does not contain an nos gene, reduced the rate and amount of intracellular ACR accumulation. However, as the reaction of ACR with NO + only partially reduced the differential sensitivity of the Dnos strain, other mechanisms beyond detoxification of ACR by NO were suspected. Turning to their previous work that NO protects against oxidative damage and armed with the knowledge that antibiotics kill by inducing oxidative damage, the authors set out to determine if NOS reduced ACR efficacy indirectly through an ROS-based mechanism. A major source of ROS is the Fenton reaction, in which peroxide reacts with ferrous iron to generate hydroxyl radicals. Bipyridyl (BP) is known to suppress the Fenton reaction by chelating cellular iron. BP addition prior to ACR treatment protected cells from ACR. Finally, pretreatment with NO protected the cells from ACR as effectively as BP, but did not further protect cells already pretreated with BP. The common but nonsynergistic effect between NO and BP provides support for the idea that both chemicals act by suppressing Fenton chemistry. The selective pressure for maintaining nos in soil bacteria cannot be to survive against synthetic antibiotics that they never encounter, but could NOS-containing bacteria meet similar stresses in their natural environment? The authors addressed this issue by investigating the effects of pyocyanin (PYO, Figure 1B) , a natural toxin chemically related to ACR that is produced by Pseudomonas aeruginosa, a soil bacterium that shares the same habitat as B. subtilis. Through a set of experiments similar to those carried out with ACR, it was shown that the nos gene or treatment with NO protects B. subtilis from PYO. Furthermore, in co-culturing experiments, killing of B. subtilis by P. aeruginosa was increased when P. aeruginosa makes PYO and when B. subtilis cannot make NO. During stationary phase, PYO promotes superoxide formation through redox cycling. The authors then demonstrated that SOD activity is linked to both PYO protection and NOS. Deletion of the B. subtilis gene for superoxide dismutase (sodA) increased PYO sensitivity, whereas expression of sodA increased in wt cells but not in Dnos cells during late exponential phase. Hence there appears to be some form of sodA regulation by nos.
In addition to the quinolone, endogenous NO was also shown to protect against another class of antibiotics, the lactams, which act to inhibit bacterial cell wall synthesis (Payne et al., 2007) . Cefuroxime (CEF, Figure 1C ) kills S. aureus and B. subtilis nos mutants more effectively than the corresponding wt cells. Similar to ACR and PYO, pretreatment with exogenous NO protects the cells against CEF. Again the link appears to be through oxidative damage induced through metabolic feedback. The addition of BP or the radical scavenger thiourea limits both killing and the ability of NO production to confer a selective advantage.
nos gene expression did not change in response to CEF treatment, but an increase in nitrite/nitrate, oxidation end products of NO was detected. This was corroborated by direct detection of NO by a specific fluorescent probe.
Thus, an innovative high throughput screen has led to the discovery that NO benefits bacteria in their struggle against certain types of antibiotics. The mechanisms behind this protection may be complex and depend upon the specific compound and organism, but there is strong evidence for the involvement of oxidative damage and its prevention by NO (Figure 2) . This in itself is quite curious, because macrophages kill pathogens through NO production in the oxidative burst, where NO combines with ROS to produce even more toxic agents (Alderton et al., 2001; Guzik et al., 2003) . NO seems to be playing for both teams. Nonetheless, a number of pathogens such as Bacillus anthracis, Bacillus cereus, S. aureus and Staphylococcus epidermidis possess NOSs, and NOS inhibition may be a viable route to increase the efficacy of drug therapies against these organisms. However, NOS inhibition is a tricky game, as work with the mammalian NOS isozymes has shown (Alderton et al., 2001; Li and Poulos, 2005; Garcin et al., 2008; Ji et al., 2009) . For NOS inhibition to be effective, it has to be specific, as one would not want to perturb the closely related host enzymes, especially if they defend against the pathogen. We have, however, learned a great deal about isozyme-specific inhibition through work with the mammalian enzymes, and this knowledge may be transferable to the bacterial systems. Finally, it should be noted that the biological functions of bacterial NOS are not limited to protection against oxidative damage. In the radiation-resistant bacterium Deinococcus radiodurans, NO protects against UV radiation by mechanisms that do not appear to primarily involve ROS (Patel et al., 2009) . In Streptomyces, NOS functions in a specific biosynthetic nitration reaction (Kers et al., 2004) . Thus, as with mammals, NOS-derived NO may play different roles in different bacteria. As Nudler and colleagues have shown, some of these functions may have important implications for human health. 
